Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

IGIP19009 / CL-SBP-101-03-Sun BioPharma / Aram Hezel

Research Question:
What is the safety, tolerability, and pharmacokinetics of SBP-101 when combined with nab-paclitaxel and gemcitabine in patients with untreated pancreatic cancer?

Basic Study Information

Purpose:
This is an open-label phase 1A/1B study to assess the safety, tolerability and pharmacokinetics of SBP-101 when combined with nab-paclitaxel and gemcitabine in subjects with previously untreated metastatic pancreatic ductal adenocarcinoma and to identify a recommended phase 2 dose. The study will also assess preliminary efficacy of the 3-drug treatment combination.

Location: University of Rochester Medical Center
Study Reference #: IGIP19009

Lead Researcher (Principal Investigator)

Lead Researcher:  Aram Hezel

Study Contact Information

Study Coordinator: Tina Bowdish
Phone: +1 585-275-9475
Email: tina_bowdish@urmc.rochester.edu

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search